期刊
STEM CELL REVIEWS AND REPORTS
卷 10, 期 2, 页码 177-190出版社
SPRINGER
DOI: 10.1007/s12015-013-9487-7
关键词
Reprogramming; Pluripotency; Induced pluripotent stem cells; Cardiac differentiation; Patient-specific stem cells; Cardiac disease models; Cardiac tissue engineering; Regenerative medicine
资金
- Fundacao para a Ciencia e Tecnologia (FCT) [SFRH/BPD/66897/2009]
- POPH - QREN - Advanced Formation
- Social European Fund
- National Fund from MCTES
- NIH [HL076485, EB 17103, EB 002520, HL108668]
- NYSTEM [C026449]
- Fundação para a Ciência e a Tecnologia [SFRH/BPD/66897/2009] Funding Source: FCT
The recent availability of human cardiomyocytes derived from induced pluripotent stem (iPS) cells opens new opportunities to build in vitro models of cardiac disease, screening for new drugs, and patient-specific cardiac therapy. Notably, the use of iPS cells enables studies in the wide pool of genotypes and phenotypes. We describe progress in reprogramming of induced pluripotent stem (iPS) cells towards the cardiac lineage/differentiation. The focus is on challenges of cardiac disease modeling using iPS cells and their potential to produce safe, effective and affordable therapies/applications with the emphasis of cardiac tissue engineering. We also discuss implications of human iPS cells to biological research and some of the future needs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据